DK1432737T3 - Humant mini-antistof cytotoxisk for tumorceller der udtrykker ERBB2-receptoren - Google Patents

Humant mini-antistof cytotoxisk for tumorceller der udtrykker ERBB2-receptoren

Info

Publication number
DK1432737T3
DK1432737T3 DK02784853.0T DK02784853T DK1432737T3 DK 1432737 T3 DK1432737 T3 DK 1432737T3 DK 02784853 T DK02784853 T DK 02784853T DK 1432737 T3 DK1432737 T3 DK 1432737T3
Authority
DK
Denmark
Prior art keywords
tumor cells
cells expressing
erbb2 receptor
human mini
erbb2
Prior art date
Application number
DK02784853.0T
Other languages
English (en)
Inventor
Alessio Giuseppe D
Renata Piccoli
Lorenzo Claudia De
Donald Balfour Palmer
Mary Alice Ritter
Original Assignee
Biotecnol Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotecnol Sa filed Critical Biotecnol Sa
Application granted granted Critical
Publication of DK1432737T3 publication Critical patent/DK1432737T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK02784853.0T 2001-07-10 2002-07-10 Humant mini-antistof cytotoxisk for tumorceller der udtrykker ERBB2-receptoren DK1432737T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001RM000408A ITRM20010408A1 (it) 2001-07-10 2001-07-10 Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.
PCT/EP2002/007671 WO2003006509A2 (en) 2001-07-10 2002-07-10 Human mini-antibody cytotoxic for tumor cells which express the erbb2 receptor

Publications (1)

Publication Number Publication Date
DK1432737T3 true DK1432737T3 (da) 2010-02-08

Family

ID=11455653

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02784853.0T DK1432737T3 (da) 2001-07-10 2002-07-10 Humant mini-antistof cytotoxisk for tumorceller der udtrykker ERBB2-receptoren

Country Status (13)

Country Link
US (2) US7585952B2 (da)
EP (1) EP1432737B1 (da)
AT (1) ATE445646T1 (da)
CA (1) CA2453435A1 (da)
DE (1) DE60234041D1 (da)
DK (1) DK1432737T3 (da)
ES (1) ES2334895T3 (da)
IT (1) ITRM20010408A1 (da)
NZ (1) NZ531035A (da)
PT (1) PT1432737E (da)
SI (1) SI1432737T1 (da)
WO (1) WO2003006509A2 (da)
ZA (1) ZA200401044B (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITFI20010114A1 (it) * 2001-06-22 2002-12-22 Univ Firenze Glicopeptidi,loro preparazione e loro uso nella diagnosi o nel trattamento terapeutico della sclerosi multipla
CN102580084B (zh) 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
US20100015661A1 (en) * 2006-04-21 2010-01-21 Mab-Factory Gmbh Antibody-rnase-conjugate
US8350011B2 (en) * 2006-08-04 2013-01-08 Medimmune Limited Antibodies to ErbB2
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
PL2171090T3 (pl) 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
CN102421448A (zh) 2009-05-29 2012-04-18 霍夫曼-拉罗奇有限公司 Her2信号传导调控剂在表达her2的胃癌患者中
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
CA3255551A1 (en) 2010-03-26 2025-04-15 Memorial Sloan-Kettering Cancer Center MUC16 ANTIBODIES AND METHODS OF USE
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
US20120148559A1 (en) 2010-12-01 2012-06-14 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
MX2014001766A (es) 2011-08-17 2014-05-01 Genentech Inc Anticuerpos de neuregulina y sus usos.
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
BR112014012979A2 (pt) 2011-11-30 2020-10-20 Genentech, Inc. mutações erbb3 em câncer
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
US20130259867A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
US9738726B2 (en) 2013-06-11 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HER2-specific monoclonal antibodies and conjugates thereof
US10155028B2 (en) 2013-08-26 2018-12-18 Health Research, Inc. Method for prophylaxis and/or treatment of ErbB2 positive cancers
SG11201608192SA (en) 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
EA035419B9 (ru) 2014-05-29 2020-08-07 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы и способы их применения
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US10478477B2 (en) 2014-08-20 2019-11-19 Health Research, Inc. Method for prophylaxis or treatment of erbb1 positive cancers using a variant peptidase d with reduced activity
MX375669B (es) 2014-09-26 2025-03-06 Macrogenics Inc Diacuerpos monovalentes biespecificos que son capaces de unir cd19 y cd3, y usos de los mismos.
SG11201707538XA (en) 2015-03-17 2017-10-30 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07309780A (ja) * 1994-03-02 1995-11-28 N Bii T Kk 抗癌剤
US5795961A (en) * 1995-02-14 1998-08-18 Ludwig Institute For Cancer Research Recombinant human anti-Lewis b antibodies
GB9805660D0 (en) * 1998-03-18 1998-05-13 Unichema Chemie Bv Improvements in and relating to fatty acid metabolism
US6135941A (en) 1998-03-27 2000-10-24 Incyte Pharmaceuticals, Inc. Human immune system associated molecules
US6794128B2 (en) 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
WO2001014558A1 (en) * 1999-08-26 2001-03-01 Morphosys Ag Human antibodies or fragments thereof binding to hla-cw6
WO2001027279A1 (en) 1999-10-12 2001-04-19 Cambridge Antibody Technology Human anti-adipocyte monoclonal antibodies and their use

Also Published As

Publication number Publication date
EP1432737B1 (en) 2009-10-14
WO2003006509A2 (en) 2003-01-23
SI1432737T1 (sl) 2010-02-26
ATE445646T1 (de) 2009-10-15
NZ531035A (en) 2005-04-29
ZA200401044B (en) 2004-10-22
WO2003006509A3 (en) 2003-11-20
US20100173978A1 (en) 2010-07-08
CA2453435A1 (en) 2003-01-23
ITRM20010408A1 (it) 2003-01-10
ES2334895T3 (es) 2010-03-17
ITRM20010408A0 (it) 2001-07-10
DE60234041D1 (de) 2009-11-26
EP1432737A2 (en) 2004-06-30
US7585952B2 (en) 2009-09-08
PT1432737E (pt) 2010-02-17
US20070258985A1 (en) 2007-11-08
US8227585B2 (en) 2012-07-24

Similar Documents

Publication Publication Date Title
DK1432737T3 (da) Humant mini-antistof cytotoxisk for tumorceller der udtrykker ERBB2-receptoren
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
IN2009KN02655A (da)
MY154009A (en) Anti-alpha v beta 6 antibodies
EP1187591A4 (en) MICROBIAL ANTIGENS ASSOCIATED WITH INFLAMMABLE COLON DISEASES (IBD) AND METHODS OF USE THEREOF
NZ600584A (en) Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
SA523440043B1 (ar) أجسام مضادة ضد cd3 إبسيلون جديدة
SG151284A1 (en) Antibodies against ccr5 and uses thereof
WO2005012493A3 (en) Anti-cd19 antibodies
TR200102733T2 (tr) IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
SI2345671T1 (sl) Optimizirane Fc-variante in postopki za njihovo izdelavo
WO2004001381A8 (en) Novel raag10 cell surface target and a family of antibodies recognizing that target
MX337423B (es) Antagonistas anti-beta7 humanizados y usos para los mismos.
WO2004029092A3 (fr) Anticorps pour adcc et induisant la production de cytokines.
AU2003215188A8 (en) Fusion proteins of humanized g250 specific antibodies and uses thereof
DE602006013029D1 (de) Anti-egfr-antikörper
PE20070374A1 (es) ANTICUERPOS ANTI-MAdCAM
GB0426146D0 (en) Therapeutic peptides and method
WO2004108766A3 (en) Anti-hgf-r antibodies and their use
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
WO2006084092A3 (en) Antibodies to oncostatin m receptor
WO2006084078A3 (en) Jam-3 and antibodies that bind thereto
WO2004094473A3 (en) Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
WO2006084075A3 (en) Adam-9 modulators